Cytokinetics CYTK
Valuation
Multiples measured against the stock's own five-year history
Above its usual level · 65th percentile, 5-year average -10.6x
Below its usual level · 25th percentile, 5-year average -44.9x
Below its usual level · 31st percentile, 5-year average 459.8x
#4910 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -24.34 | – | -44.91 | 25% (cheaper than usual) | – |
| PE | -9.32 | -10.32 | -10.58 | 65% (pricier than usual) | – |
| PS | 69.02 | 21.59 | 459.79 | 31% (cheaper than usual) | #4910 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on CYTK.
Sign in to join the discussion.